Abstract
Objective: Fibromyalgia is a chronic pain condition characterised by widespread pain, fatigue, and cognitive function impairment. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aimed to identify predictors of response to systemic lidocaine to enable targeted treatment for individuals more likely to benefit. Methods: It was a retrospective study at a tertiary pain centre. Adult patients who have completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg. Results: We identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female compared to 4.2% in male patients. There was no significant difference in demographic characteristics, pain severity, and sleep interference between male and female patients, except for a higher score in functional impairment among females. Responders were younger, had shorter pain duration, and had lower weekly pain scores. No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. Conclusions: IV lidocaine infusion proves effective, especially for younger female patients. It should be added to conventional therapies for these patients. More research is needed on gender differences and fibromyalgia subtypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a registry study that doesn't require ethical approval in the UK. The project has been approved by Guy's and St. Thomas Hospital's Electronic Records Research Interface (GERRI) to utilise routinely collected patient data from Guy's and St. Thomas Hospital (GSTT). The data was analysed in a pseudonymised format with GSTT platform.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos